NeoStem to Present at Multiple October Conferences

NeoStem Inc. Logo

NEW YORK, Sept. 30, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy ("PCT"), will present at multiple upcoming conferences in October.

2013 RAPS (Regulatory Affairs Professional Society): The Regulatory Convergence

  • Date and Time: Tuesday, October 1, 3:00 PM EDT
  • Venue: John B. Hynes Veterans Memorial Convention Center, Boston, MA
  • Session: Regulatory Requirements for Cell Therapy Tools
  • Speaker: Robert A. Preti, Ph.D., Chief Scientific Officer, NeoStem, and President, PCT

U.S. Food and Drug Administration (FDA) Public Workshop: Synergizing Efforts in Standards Development for Cellular Therapies and Regenerative Medicine Products

  • Date and Time: Monday, October 7, 11:20 AM EDT
  • Venue: FDA White Oak Campus, Silver Spring, MD
  • Session: Professional Societies, Industry Organizations, and Standards Related Organizations
  • Speaker: Robert A. Preti, Ph.D., Chief Scientific Officer, NeoStem, and President, PCT

BIO Investor Forum San Francisco

  • Date and Time: Wednesday, October 9, 10:30 AM PDT
  • Venue: The Palace Hotel, San Francisco, CA
  • Session: Company Presentation
  • Speaker: Robin L. Smith, MD, MBA, Chairman and CEO, NeoStem

Stem Cell Meeting on the Mesa

  • Venue: Estancia La Jolla Hotel & Spa, La Jolla, CA
  • Session #1 Date and Time: Tuesday, October 15, 8:45 AM PDT
  • Session#1: Regulatory Challenges & Strategies For Regen Med Companies
  • Speaker #1: Robert A. Preti, Ph.D., Chief Scientific Officer, NeoStem, and President, PCT
  • Session #2 Date and Time: Tuesday, October 15, 11:15 AM PDT
  • Session #2: Company Presentation, NeoStem
  • Speaker #2: Robin L. Smith, MD, MBA, Chairman and CEO, NeoStem
  • Session #3 Date and Time: Tuesday, October 15, 3:00 PM PDT
  • Session #3: Company Presentation, PCT
  • Speaker #3: Robert A. Preti, Ph.D., Chief Scientific Officer, NeoStem, and President, PCT

IBC's 3rd Annual Cell Therapy Bioprocessing

  • Venue: Bethesda Marriott, Bethesda, MD
  • Session #1 Date and Time: Monday, October 21, 8:45 AM EDT
  • Session #1: Challenges and Future Directions for Commercial Scale Patient-Specific Production
  • Speaker #1: Brian Hampson, Senior Director, Innovation and Engineering
  • Session #2 Date and Time: Monday, October 21, 1:25 PM EDT
  • Session #2: Process Development for Commercial Success
  • Speaker #2: Robert Shaw, Vice President, Commercial Development

New York Society of Security Analysts' 17th Annual Life Science Conference

  • Date and Time: Wednesday, October 30, 10:00 EDT
  • Venue: NYSSA Conference Facilities , New York, NY
  • Session: Company Presentation
  • Speaker: Robin L. Smith, MD, MBA, Chairman and CEO

About NeoStem, Inc.

NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

For more information on NeoStem, please visit www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's research and development and clinical evaluation efforts as well as efforts towards commercialization of cellular therapies, including with respect to AMR-001, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company's ability to successfully grow its contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: NeoStem Eric Powers Manager of Communications and Marketing Phone: +1-212-584-4173 Email: epowers@neostem.com

Source:NeoStem Inc.